Ustekinumab (STELARA), binds and inhibits the p40 molecular subunits of both IL-12 and IL-23 thus blocking their action in inducing pathogenic CD4 Th1 and Th17 T cell subsets.9 Our overarching hypothesis is that interrupting the IL-17 and IFN-γ axes in individuals with recent-onset T1D will halt or slow the autoimmune destruction of beta cells sufficiently to permit beta cell preservation and maintain residual physiological insulin secretion. The gene discussed is INS; the disease is type 1 diabetes mellitus.